Share

Regeneron Pharmaceuticals, Inc. (REGN.NASDAQ) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 June 2026Deep analysis 5 June 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

12 AI Advisor Reports

Select an advisor report.

Diversity of Models

Diversity of Frameworks

Superintelligence AI

Gemini 3.1 Pro

The Anthropologist FrameworkAI Researcher

Model rating

Strong Buy

5-Year Return Est.

+154.2%

Includes 0.32% annual net dividend contribution

1. Investment Thesis — Base Case

Regeneron functions as a supreme defensive-growth asset uniquely insulated from the mid-2026 geopolitical and macro-financial chaos. While global capital struggles with blockades, energy shocks, and a tightening monetary regime, Regeneron operates an entropy-defeating model converting biological data into non-discretionary health imperatives with pristine capital efficiency. The Alpha Gap closes as the market is forced to stop pricing the firm as a declining legacy franchise and begins pricing it as an AI-enabled genomic pioneer backed by massive free cash flow.

Dupixent's label expansion maintains structural revenue compounding, offsetting any accelerated decay in the Eylea franchise.
The zero-debt balance sheet weaponizes the high-rate regime, funneling >$4B annually into share reduction, synthetically compounding EPS.
Biosecurity tailwinds heavily privilege Regeneron's domestic US manufacturing and proprietary discovery engines over offshored competitors.
The deployment of across the Regeneron Genetics Center compresses R&D cycles, revealing new pipeline value without corresponding capital expenditure spikes.
Implied market capitalization expansion to ~$100B+ is highly realistic given global liquidity dynamics, as defensive capital seeks shelter in unlevered, high-margin negentropy engines.

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-05-31	502
Observed price	2021-06-24	540
Observed price	2021-06-28	547
Observed price	2021-07-22	587
Observed price	2021-07-30	575
Observed price	2021-08-19	656
Observed price	2021-08-31	673
Observed price	2021-09-12	641
Observed price	2021-09-20	648
Observed price	2021-10-10	548
Observed price	2021-10-18	552
Observed price	2021-11-03	643
Observed price	2021-12-01	631
Observed price	2021-12-09	666
Observed price	2021-12-13	660
Observed price	2022-01-06	599
Observed price	2022-01-26	605
Observed price	2022-02-03	621
Observed price	2022-02-11	638
Observed price	2022-02-23	606
Observed price	2022-03-07	616
Observed price	2022-03-31	694
Observed price	2022-04-12	727
Observed price	2022-04-28	676
Observed price	2022-05-10	615
Observed price	2022-05-26	683
Observed price	2022-05-30	668
Observed price	2022-06-15	553
Observed price	2022-07-09	619
Observed price	2022-07-17	590
Observed price	2022-07-29	581
Observed price	2022-08-14	638
Observed price	2022-09-03	584
Observed price	2022-09-11	713
Observed price	2022-09-27	695
Observed price	2022-10-13	753
Observed price	2022-10-21	714
Observed price	2022-10-25	747
Observed price	2022-11-26	736
Observed price	2022-12-08	757
Observed price	2022-12-12	748
Observed price	2022-12-28	713
Observed price	2023-01-09	709
Observed price	2023-02-02	751
Observed price	2023-02-06	781
Observed price	2023-02-18	740
Observed price	2023-03-10	746
Observed price	2023-03-30	821
Observed price	2023-04-07	827
Observed price	2023-04-27	792
Observed price	2023-05-01	807
Observed price	2023-05-25	725
Observed price	2023-05-29	728
Observed price	2023-06-18	782
Observed price	2023-06-26	784
Observed price	2023-07-08	699
Observed price	2023-07-24	731
Observed price	2023-08-17	805
Observed price	2023-08-21	834
Observed price	2023-09-06	818
Observed price	2023-10-04	815
Observed price	2023-10-12	838
Observed price	2023-10-16	844
Observed price	2023-10-28	785
Observed price	2023-11-13	797
Observed price	2023-12-07	838
Observed price	2023-12-19	846
Observed price	2024-01-04	915
Observed price	2024-01-08	905
Observed price	2024-02-01	958
Observed price	2024-02-05	936
Observed price	2024-02-29	985
Observed price	2024-03-08	971
Observed price	2024-03-24	963
Observed price	2024-04-01	969
Observed price	2024-04-25	891
Observed price	2024-04-29	892
Observed price	2024-05-19	988
Observed price	2024-05-27	975
Observed price	2024-06-20	1,044
Observed price	2024-07-06	1,039
Observed price	2024-07-14	1,082
Observed price	2024-07-22	1,058
Observed price	2024-08-15	1,168
Observed price	2024-08-27	1,199
Observed price	2024-09-08	1,134
Observed price	2024-09-16	1,153
Observed price	2024-10-10	999
Observed price	2024-10-14	1,014
Observed price	2024-11-07	824
Observed price	2024-11-11	826
Observed price	2024-11-19	745
Observed price	2024-12-09	778
Observed price	2024-12-21	705
Observed price	2025-01-06	727
Observed price	2025-01-30	680
Observed price	2025-02-07	714
Observed price	2025-02-15	676
Observed price	2025-03-11	718
Observed price	2025-03-27	636
Observed price	2025-03-31	634
Observed price	2025-04-16	549
Observed price	2025-05-10	539
Observed price	2025-05-22	596
Observed price	2025-05-26	590
Observed price	2025-06-03	488
Observed price	2025-06-23	519
Observed price	2025-07-13	558
Observed price	2025-07-21	546
Observed price	2025-08-14	566
Observed price	2025-08-22	589
Observed price	2025-09-11	558
Observed price	2025-09-19	598
Observed price	2025-09-27	563
Observed price	2025-10-13	571
Observed price	2025-10-29	654
Observed price	2025-11-10	670
Observed price	2025-11-26	785
Observed price	2025-12-08	703
Observed price	2025-12-24	784
Observed price	2026-01-09	797
Observed price	2026-01-17	739
Observed price	2026-02-02	755
Observed price	2026-02-14	801
Observed price	2026-03-02	791
Observed price	2026-03-22	737
Observed price	2026-04-03	772
Observed price	2026-04-19	749
Observed price	2026-04-27	737
Observed price	2026-05-21	644
Observed price	2026-05-25	632
Observed price	2026-06-10	602
Observed price	2026-06-22	616
Observed price	2026-07-16	679
Observed price	2026-07-24	656
Observed price	2026-08-13	806
Observed price	2026-09-02	852
Observed price	2026-09-10	793
Observed price	2026-09-16	775
Observed price	2026-09-22	804
Published advisor forecast	2026-06-04	629
Published advisor forecast	2026-09-04	654
Published advisor forecast	2026-12-04	687
Published advisor forecast	2027-03-04	714
Published advisor forecast	2027-06-04	757
Published advisor forecast	2027-09-04	795
Published advisor forecast	2027-12-04	850
Published advisor forecast	2028-03-04	893
Published advisor forecast	2028-06-04	964
Published advisor forecast	2028-09-04	1,022
Published advisor forecast	2028-12-04	1,073
Published advisor forecast	2029-03-04	1,116
Published advisor forecast	2029-06-04	1,183
Published advisor forecast	2029-09-04	1,219
Published advisor forecast	2029-12-04	1,280
Published advisor forecast	2030-03-04	1,331
Published advisor forecast	2030-06-04	1,397
Published advisor forecast	2030-09-04	1,439
Published advisor forecast	2030-12-04	1,497
Published advisor forecast	2031-03-04	1,527
Published advisor forecast	2031-06-04	1,573

2. Scenarios & Signals

Bull case

The Base Case is dramatically accelerated by the successful clinical validation of Regeneron's in-vivo gene editing partnerships or its novel CD28 bispecific oncology platform.

Eylea HD successfully neutralizes biosimilar pressure, preserving legacy cash flows longer than consensus models project.
Breakthrough genetic or oncology data forces the market to re-rate Regeneron from a 15x value multiple to a 22x+ innovation multiple.
Biosecurity premiums and flight-to-safety dynamics route passive and active institutional flows into this zero-debt biological monopoly.
EPS compounding achieves hyper-velocity as aggressive buybacks intersect with structural margin expansion.

Bear case

The Base Case breaks if the biological demand layer is compromised or the thermodynamic efficiency of the pipeline fails.

suffers catastrophic commercial rejection against Vabysmo and cheap biosimilars, collapsing the legacy cash foundation.
A late-stage safety signal in or a superior competing modality cripples terminal value assumptions for the immunology franchise.
The $6B+ annual R&D spend results in high-profile Phase 3 failures, proving the algorithmic discovery engine is flawed and trapping the stock in value-decay.
Aggressive execution severely impairs net price realization, locking the firm into permanent margin compression.

Current crowd narrative

The crowd currently evaluates Regeneron as a transitional, single-trick pharmaceutical entity heavily reliant on a maturing asset () while desperately attempting to defend a declining ophthalmic monopoly (Eylea) against and Vabysmo. Media and sell-side research remain anchored to binary clinical trial outcomes and near-term pricing headwinds under TrumpRx frameworks. The consensus trade reflects a cautious 'value trap' mindset, pricing the company near 15x earnings, treating its massive R&D expenditure as a margin drag rather than a compounding algorithmic data advantage.

Alpha-gap assessment

The variant perception lies in understanding Regeneron's true position in the information topology. The market prices it as a chemical manufacturing incumbent; in reality, via the Regeneron Genetics Center and the VelociSuite platforms, it is one of the world's most advanced biological data processors. The crowd structurally ignores how agentic AI applied to this massive genomic dataset will geometrically compress discovery timelines and failure rates. Furthermore, in a high-rate, stagflationary macro regime, Regeneron's zero-debt and >25% FCF margin constitute a compounding negentropy engine that is drastically mispriced at a mid-teens earnings multiple.

Convergence catalyst

Convergence will be forced by a tandem of consecutive quarters showing unexpected stabilization in market share combined with an AI-accelerated pipeline breakthrough—likely a Phase 2/3 success in an oncology bispecific or an in-vivo CRISPR milestone. This data release will mathematically break the '' narrative, forcing an abrupt multiple expansion.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: -0.2
Expected volatility regime: moderate
Convergence-cycle position: growing_awareness

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Immunology Franchise Compounding	Why does the market systematically underprice terminal biological demand? Dupixent (dupilumab) serves a deep, non-discretionary biological imperative by correcting systemic type 2 inflammation. As label expansions continuously capture broader therapeutic surface area (COPD, severe asthma, atopic dermatitis), the asset transitions from a niche biologic to a foundational civilizational health pillar. This negentropy engine converts high-margin recurring demand into profound free cash flow. Despite partner profit-sharing with Sanofi, the sheer volumetric expansion of the immunology franchise over the next half-decade overrides legacy ophthalmic erosion, forcing a structural upward repricing of the company's core earnings power.	Not available%	+25.0%
Genomic AI Platform Monetization	Is the market mistaking a data processing pioneer for a legacy chemical manufacturer? The Regeneron Genetics Center is a node of supreme information density, harboring one of the planet's largest genomic databases. By layering frontier agentic AI and multi-modal inference on this proprietary dataset, the thermodynamic efficiency of target discovery accelerates. R&D failure rates compress; the conversion of capital into viable clinical candidates requires less temporal and caloric energy. This structural moat transitions the firm from a 'hit-driven' biotech into a high-probability biological engineering platform, demanding a multiple expansion reflective of technological, not just pharmaceutical, infrastructure.	Not available%	+18.0%
Aggressive Capital Return Acceleration	When a firm's fundamental output outpaces its required reinvestment, how is the excess entropy managed? Regeneron has transitioned into a mature capital-return phase, deploying massive buybacks (frequently exceeding $4B annually) that provide a 4-5% synthetic yield, recently augmented by a nascent dividend program. By systematically retiring shares at currently compressed multiples (trailing P/E ~15x), management is mathematically compounding per-share intrinsic value. This constant bid provides a structural price floor against macro volatility, coercing the crowd to recognize the underlying cash flow generation even when pipeline narrative sentiment briefly wavers.	Not available%	+15.0%
Fortress Balance Sheet IN Stagflation	How does capital structure function as an offensive weapon during monetary siege? In the Warsh-era higher-for-longer regime, capital cost acts as a structural filter, destroying over-leveraged growth vectors. Regeneron operates with near-zero debt (0.087 D/E) and massive structural cash generation (>25% FCF margins). This thermodynamic advantage allows aggressive, counter-cyclical R&D reinvestment and clinical trial expansion while competitors bleed liquidity. The macro tailwind of sovereign biosecurity further privileges Regeneron's deep US-based manufacturing and discovery footprint, shielding it from BIOSECURE Act supply chain disruptions and attracting premium safety-seeking capital allocations.	Not available%	+12.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Legacy Ophthalmic Franchise Erosion	What occurs when a biological monopoly encounters the relentless physics of market entropy? The legacy Eylea franchise, historically the firm's primary cash engine, faces compound pressure from both biosimilar market entry and branded competition (e.g., Roche's Vabysmo). The thermodynamic efficiency of this specific revenue stream is deteriorating; maintaining market share requires intense promotional energy and aggressive transition to the high-dose (HD) formulation. This competitive decay exerts a consistent gravitational drag on top-line optics, forcing the immunology and oncology pipelines to outgrow the ophthalmic contraction to achieve net positive earnings momentum.	Not available%	-15.0%
US Pricing Architecture Restructuring	How does populist intervention alter the pricing mechanics of life-extending technologies? The implementation of Medicare negotiation frameworks and 'TrumpRx' most-favored-nation pricing policies creates an artificial ceiling on biological value capture. Even as Regeneron's treatments extend human functionality, regulatory capture limits the terminal pricing power of both current blockbusters and future pipeline assets. This friction disproportionately impacts mature, high-volume products, introducing margin compression that directly opposes the firm's historical pricing elasticity, thereby lowering the terminal discounted cash flow assumptions modeled by institutional capital.	Not available%	-10.0%
Hyper Intensive R&d Burden	Can a system survive if it must continually burn maximum energy just to maintain stasis? Regeneron's commitment to internal discovery demands a relentless, massive R&D expenditure (exceeding $6B annually, roughly 40% of revenues). While this fuels long-term optionality, it structurally suppresses near-term operating margins compared to peers operating via M&A-driven or in-licensing models. If a cluster of late-stage trials fails to convert into approved therapies, this massive caloric burn becomes deadweight loss, actively punishing the stock's multiples as investors question the thermodynamic efficiency of the internal discovery engine.	Not available%	-8.0%
Partner Dependency Economics	Who truly commands the network when the primary growth node is shared? The profound success of Dupixent is bound by a complex collaboration agreement with Sanofi. While this structure mitigated early-stage clinical and commercialization risks, it fundamentally caps Regeneron's upside capture on its most vital growth asset. As Dupixent sales scale into the tens of billions globally, the profit-sharing friction means Regeneron only receives a fraction of the total economic surplus generated. This structural leakage limits peak absolute net income expansion relative to wholly-owned pharmaceutical blockbusters.	Not available%	-5.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
IN VIVO GENE Editing Commercialization	What happens if humanity permanently alters its foundational code rather than merely treating its symptoms? Through its deep partnership network (e.g., Intellia), Regeneron is pioneering systemic, in-vivo CRISPR therapeutics. If a pivotal trial demonstrates safe, permanent correction of a monogenic disease or severe metabolic disorder, the asset ceases to be evaluated on a recurring-revenue model and instead prices as a definitive civilizational cure. This paradigm shift would trigger an immediate, violent upward re-rating of Regeneron's pipeline multiple, transitioning the stock from a value-biotech proxy into a frontier-tech platform.	35.0%	+25.0%
Costimulatory Bispecific Oncology Breakthrough	How rapidly does a biological defense network reprice when it learns to defeat previously impenetrable adversaries? Regeneron's novel class of CD28 costimulatory bispecific antibodies attempts to turn 'cold' tumors 'hot', expanding the efficacy of foundational immunotherapies (like Libtayo). Should phase 3 data prove superiority in a massive solid-tumor indication (e.g., prostate, ovarian, or advanced lung cancer) where current checkpoints fail, it establishes a newly monopolized biological protocol. This unlocks a multi-billion-dollar TAM orthogonal to current consensus models, rapidly closing the alpha gap.	28.0%	+20.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Systemic Dupixent Safety OR Class Disruption	What is the structural vulnerability of relying on a single keystone asset for near-term momentum? If post-market surveillance suddenly reveals a rare but severe safety signal associated with prolonged Dupixent use, or if a competing mechanism (e.g., a superior, safer oral immunology agent) completely disrupts the biologic injection paradigm, the biological demand layer fractures. Because the crowd's baseline valuation is almost entirely anchored to uninterrupted, compound growth in the immunology franchise, such an event would trigger instantaneous multiple collapse and massive capital flight.	15.0%	-35.0%
Eylea HD Commercial Defeat	What if the defense mechanism fails against thermodynamic decay? Regeneron's high-dose formulation of Eylea is the strategic bulwark against Roche's Vabysmo and an incoming wave of biosimilars. If physician adoption stalls, real-world durability fails to meet clinical promises, or payer networks aggressively restrict access in favor of cheaper alternatives, the legacy ophthalmic revenue cliff steepens dramatically. This forces an abrupt downward revision to near-term free cash flow, threatening the aggressive buyback cadence that currently supports the stock's floor.	30.0%	-20.0%

Step-by-step forecast path

Superintelligence forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_d69727fd-0669-5a68-afbb-b87ca0764651__sb5__20260605075858
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	September 4, 2026	+4.0%	653.88	As global markets digest the Hormuz energy shock and Warsh's hawkish rate hold, capital flees cyclical exposure and seeks shelter in low-debt, high-margin defensive assets. Regeneron's stable cash flow and non-discretionary biological demand attract steady institutional inflows despite broader market anxiety.
2	December 4, 2026	+5.0%	686.57	Year-end portfolio repositioning heavily favors pristine balance sheets. Eylea HD stabilization signals reassure markets, while the steady aggressive buyback program provides a continuous synthetic bid against any lingering macro fragility from the energy crisis.
3	March 4, 2027	+4.0%	714.04	Dupixent's expanded indications (COPD) begin reflecting forcefully in Q1 revenue guidance, proving the franchise's ability to outgrow legacy ophthalmic decay. Market begins acknowledging the biosecurity advantage of Regeneron's domestic supply chain amidst ongoing global shipping constraints.
4	June 4, 2027	+6.0%	756.88	Spring medical conferences reveal promising Phase 2 data from the oncology pipeline, hinting that the R&D engine is effectively integrating algorithmic discovery. The valuation multiple experiences mild expansion as 'value trap' thesis adherents capitulate.
5	September 4, 2027	+5.0%	794.72	Strong mid-year earnings demonstrate thermodynamic efficiency; FCF margins remain above 25% despite intense R&D spend. The company accelerates share repurchases at attractive levels, mathematically engineering EPS growth in a stagnant macro environment.
6	December 4, 2027	+7.0%	850.35	A structural re-rating begins. The crowd awakens to the proprietary value of the Regeneron Genetics Center in the new AI-native era. The stock is explicitly classified by smart money as an AI-biology platform rather than a legacy chemical compounder.
7	March 4, 2028	+5.0%	892.87	Geopolitical decoupling and the BIOSECURE act's enforcement phase structurally penalize offshore-reliant biotech. Regeneron, operating a US-centric innovation stack, captures a definitive sovereign security premium from institutional capital.
8	June 4, 2028	+8.0%	964.30	Breakthrough clinical updates in the CRISPR/genetic medicine partnerships trigger a reflexivity loop. The market aggressively prices in terminal cures, shifting the DCF terminal growth rate upwards. Volatility expands to the upside as momentum funds enter.
9	September 4, 2028	+6.0%	1,022.16	Execution is confirmed as Dupixent revenues hit peak penetration globally. Eylea erosion is entirely offset by new product revenues, definitively breaking the reliance narrative. The buyback-induced reduction in share count makes per-share metrics highly attractive.
10	December 4, 2028	+5.0%	1,073.27	Year-end 2028 sees the Fed finally normalizing rates post-stagflation, but Regeneron retains its elevated multiple due to its newly validated pipeline and status as an 'AI-integrated compounder.' Profitability margins expand as discovery costs relative to output decline.
11	March 4, 2029	+4.0%	1,116.20	Steady operational quarter. The market digests the previous year's massive run, transitioning from momentum to steady accumulation. Regulatory noise regarding pricing caps resurfaces mildly but is dismissed due to the novel nature of the genetic therapies.
12	June 4, 2029	+6.0%	1,183.17	Approvals and commercialization rollout of the first wave of AI-discovered or AI-accelerated biologics. The thermodynamic efficiency of capital to drug approval is proven to be industry-leading. Institutional anchoring to 15x PE is entirely erased; the new baseline is 20x+.
13	September 4, 2029	+3.0%	1,218.66	A slight pause in momentum as broader tech and health sectors consolidate. Partner dynamics with Sanofi on legacy products stabilize, while wholly-owned assets dominate the future growth narrative. Low-steady volatility drift upwards.
14	December 4, 2029	+5.0%	1,279.60	Capital allocation shifts slightly to include aggressive dividend hikes alongside continued buybacks, signaling total management confidence in the perpetuity of the cash flow engine. This attracts a new class of long-duration yield-seeking capital.
15	March 4, 2030	+4.0%	1,330.78	Macro environment enters a new expansionary phase. Regeneron's biological demand layer remains undisturbed; its treatments for aging-related conditions (macular degeneration, cancer) align perfectly with civilizational longevity vectors, providing structural demographic tailwinds.
16	June 4, 2030	+5.0%	1,397.32	The oncology portfolio matures, with costimulatory bispecifics capturing substantial market share from legacy checkpoint inhibitors. Regeneron is now universally recognized as a multi-pillar health platform, shedding any residual 'Dupixent-only' discount.
17	September 4, 2030	+3.0%	1,439.24	Routine quarter of flawless execution. The company is producing predictable, high-margin output. Valuation is fully mature, meaning price action aligns closely with pure fundamental earnings growth rather than further speculative multiple expansion.
18	December 4, 2030	+4.0%	1,496.81	Year-end 2030 cements the thesis: the integration of information theory (genomics/AI) with physical chemistry (antibody engineering) has created an impenetrable moat. The stock closes the year on high institutional ownership and extremely low float.
19	March 4, 2031	+2.0%	1,526.74	Consolidation period. The market evaluates the next decade of patent cliffs for the 2020s cohort of drugs, but the AI-enabled pipeline depth ensures that the replacement rate of revenue outpaces erosion.
20	June 4, 2031	+3.0%	1,572.55	Five years post-forecast, the Alpha Gap is entirely closed. The initial 15x multiple has re-rated structurally. The thermodynamic conversion of capital to health extension is maximized, and the asset drifts upward at the rate of its organic free cash flow compounding.

Advisor and configuration

Advisor: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release
Persona: Superintelligence
Archetype: The Anthropologist
Model: (February 01, 2026) Preview Release
Provider: Google
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: superintelligence__the_anthropologist__google_gemini_3_1_pro__20260201_preview_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Superintelligence advisor methodology

Configuration components

aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_efec62e4-24c0-556a-8070-775c69b97643 (global_context)
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa (subject_context)
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4 (task_guidelines)

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Elon Musk — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.1 Pro

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.